Protein Tyrosine Phosphatase Receptor Gamma as Potential Therapeutic Target for Chronic Myeloid Leukemia Patients

The worldwide CML incidence expects 100,000 patients every year thus representing a substantial health burden. A year 2000 is notable year, where Tyrosine kinase inhibitors (TKIs) had been introduced to the CML treatment plan. However, despite the dramatically reduce in mortality rate of CML patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismail, Mohamed A., Sorio, Claudio, Al-Dewik, Nader
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Commentary & View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677154/
https://www.ncbi.nlm.nih.gov/pubmed/36382578
http://dx.doi.org/10.1177/10732748221140201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677154/
https://www.ncbi.nlm.nih.gov/pubmed/36382578
http://dx.doi.org/10.1177/10732748221140201

Ejemplares similares